Low-Concentration PTX And RSL3 Inhibits Tumor Cell Growth Synergistically By Inducing Ferroptosis In Mutant p53 Hypopharyngeal Squamous Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Yoshino T, Hasegawa Y, Takahashi S, et al. Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol. 2013;43(5):524–531. doi:10.1093/jjco/hyt03423479384
   PubMed Web of Science ®Google Scholar
• Al-Saleh K, El-Sherify M, Safwat R, et al. Phase II/III randomized controlled trial of concomitant hyperfractionated radiotherapy plus cetuximab (Anti-EGFR Antibody) or chemotherapy in locally advanced head and neck cancer. Gulf J Oncolog. 2019;1(30):6–12.
   PubMedGoogle Scholar
• Ley J, Wildes TM, Daly K, Oppelt P, Adkins D. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Med Oncol. 2017;34(2):28. doi:10.1007/s12032-017-0884-728078561
   PubMed Web of Science ®Google Scholar
• Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CJ, Long AA. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2014;2(4):428–433. doi:10.1016/j.jaip.2014.04.01025017531
   PubMed Web of Science ®Google Scholar
• Lv C, Qu H, Zhu W, et al. Low-dose paclitaxel inhibits tumor cell growth by regulating glutaminolysis in colorectal carcinoma cells. Front Pharmacol. 2017;8:244. doi:10.3389/fphar.2017.0024428522974
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20(29):3806–3813. doi:10.1038/sj.onc.120448711439344
   PubMed Web of Science ®Google Scholar
• Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang CM. Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol((R))-resistant ovarian cancer. Am J Transl Res. 2015;7(5):841–855.26175846
   PubMed Web of Science ®Google Scholar
• Imai H, Matsuoka M, Kumagai T, Sakamoto T, Koumura T. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis. Curr Top Microbiol Immunol. 2017;403:143–170. doi:10.1007/82_2016_50828204974
   PubMed Web of Science ®Google Scholar
• Latunde-Dada GO. Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta. 2017;1861(8):1893–1900. doi:10.1016/j.bbagen.2017.05.019
   PubMed Web of Science ®Google Scholar
• Schneider-Stock R, Mawrin C, Motsch C, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol. 2004;164(4):1233–1241. doi:10.1016/S0002-9440(10)63211-715039212
   PubMed Web of Science ®Google Scholar
• Omura G, Ando M, Ebihara Y, et al. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma. BMC Cancer. 2017;17:1.28049525
   PubMed Web of Science ®Google Scholar
• Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.25799988
   PubMed Web of Science ®Google Scholar
• Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26(9):1021–1032.27514700
   PubMed Web of Science ®Google Scholar
• Tarangelo A, Magtanong L, Bieging-Rolett KT, et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 2018;22(3):569–575.29346757
   PubMed Web of Science ®Google Scholar
• Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol. 1993;142(4):1131.7682763
   PubMed Web of Science ®Google Scholar
• Stewart DA, Winnike JH, McRitchie SL, Clark RF, Pathmasiri WW, Sumner SJ. Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to paclitaxel identify key metabolic differences. J Proteome Res. 2016;15(9):3225–3240.27447733
   PubMed Web of Science ®Google Scholar
• Friedmann AJ, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180–1191.25402683
   PubMed Web of Science ®Google Scholar
• Gao M, Yi J, Zhu J, et al. Role of mitochondria in ferroptosis. Mol Cell. 2019;73(2):354–363.30581146
   PubMed Web of Science ®Google Scholar
• Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59(2):298–308.26166707
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.22632970
   PubMed Web of Science ®Google Scholar
• Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1–2):317–331.24439385
   PubMed Web of Science ®Google Scholar
• Choi YH, Yoo YH. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012;28(6):2163–2169.23023313
   PubMed Web of Science ®Google Scholar
• Sui X, Zhang R, Liu S, et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol. 2018;9.29422861
   PubMed Web of Science ®Google Scholar
• Villar VH, Merhi F, Djavaheri-Mergny M, Duran RV. Glutaminolysis and autophagy in cancer. Autophagy 2015;11(8):1198–1208..
   Google Scholar
• Cetindis M, Biegner T, Munz A, Teriete P, Reinert S, Grimm M. Glutaminolysis and carcinogenesis of oral squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016;273(2):495–503.25663193
   PubMed Web of Science ®Google Scholar
• Lang I, Feuer L, Nekam K, Szigeti A, Gergely P, Petranyi G. Glutaurine enhances the depressed NK cell activity of tumor patients. Immunol Commun. 1983;12(5):519–527.6642553
   PubMedGoogle Scholar
• Albrecht J, Dolinska M, Hilgier W, Lipkowski AW, Nowacki J. Modulation of glutamine uptake and phosphate-activated glutaminase activity in rat brain mitochondria by amino acids and their synthetic analogues. Neurochem Int. 2000;36(4–5):341–347.10733001
   PubMed Web of Science ®Google Scholar
• Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2018.
   PubMed Web of Science ®Google Scholar
• Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017.
   Web of Science ®Google Scholar
• Grugan KD, Vega ME, Wong GS, et al. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol Ther. 2013;14(9):853–859.23792586
   PubMed Web of Science ®Google Scholar
• Samassekou O, Bastien N, Lichtensztejn D, Yan J, Mai S, Drouin R. Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres. Genes Chromosomes Cancer. 2014;53(11):934–950.25059482
   PubMed Web of Science ®Google Scholar
• Rieber M, Strasberg RM. DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin. Int J Cancer. 2009;125(7):1604–1612.19507255
   PubMed Web of Science ®Google Scholar
• Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–629.17311302
   PubMed Web of Science ®Google Scholar
• Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol. 2014;25(10):1889–1900. doi:10.1093/annonc/mdu14324718888
   PubMed Web of Science ®Google Scholar
• Neskey DM, Osman AA, Ow TJ, et al. Evolutionary action score ofTP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 2015;75(7):1527–1536.25634208
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Candelaria N, Wong KK, et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun. 2018;9(1):1270.29593334
   PubMedGoogle Scholar